Afatinib-associated Stevens-Johnson syndrome in an EGFR-mutated lung cancer patient.

Related Articles

Afatinib-associated Stevens-Johnson syndrome in an EGFR-mutated lung cancer patient.

Lung Cancer. 2016 May;95:35-8

Authors: Doesch J, Debus D, Meyer C, Papadopoulos T, Schultz ES, Ficker JH, Brueckl WM

Abstract
INTRODUCTION: Afatinib is a tyrosine kinase inhibitor (TKI), that has been approved for treating patients with epidermal growth factor receptor (EGFR) mutated advanced non-small-cell lung cancer (NSCLC). Stevens-Johnson syndrome (SJS) related to EGFR directed TKIs is a rare adverse event.
CASE PRESENTATION: We report a case of a 79-year-old white female with EGFR-mutated, metastatic non-small-cell lung cancer treated with afatinib as first-line palliative treatment, who developed a SJS after two months of treatment. Discontinuation of the TKI and systemic glucocorticoid treatment led to improvement of symptoms and recovery.
CONCLUSION: Severe adverse cutaneous drug reactions that predominantly involve the skin and mucous membranes during treatment with afatinib should alert clinicians to suspect SJS and react appropriately.

PMID: 27040849 [PubMed - indexed for MEDLINE]

http://ift.tt/2h5L0k8